ArticleNeuron2021
SARM1 is a metabolic sensor activated by an increased NMN/NAD
Open access · bronzeAbstract read
In one paragraph
Article in Neuron, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 194 papers.
0numbers the graph read from it
0cells of the map it votes in
194citing papers in PubMed
29.7field-weighted citation impact, top 1% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
194 citing papers in PubMed, 329 citations in OpenAlex.
- Direct activation of SARM1 by dsDNA is not supported by biochemical and cellular evidence.Proceedings of the National Academy of Sciences of the United States of America · 2026Article
- Article
- Nicotinamide Mononucleotide Adenylyltransferase 1 and NADMetabolites · 2026Review
- Review
- Peripheral Neuropathy in Metabolic Stress.International journal of molecular sciences · 2026Review
- Review
- Complex Contributions of Methylglyoxal to Pain, Axon Degeneration, and Diabetic Peripheral Neuropathy.Journal of neurochemistry · 2026Review
- Boldine inhibits SARM1 NADase Activity and Preserves Axonal Integrity After Nerve Injury.bioRxiv : the preprint server for biology · 2026Article
- Redox Molecules in Aging and Neurodegenerative Disorders.International journal of molecular sciences · 2026Review
- Tumor-derived stearic acid induces macrophage Egr2 signaling to suppress anti-tumor immunity in breast cancer.bioRxiv : the preprint server for biology · 2026Article
- Wallerian Degeneration and Nerve Regeneration-A Review of Cellular and Molecular Events.International journal of molecular sciences · 2026Review
- Bioenergetic failure in diabetic peripheral neuropathy: from glucotoxicity to multidimensional metabolic imbalance.Journal of neurology · 2026Review
- Neurodegenerative NMNAT2 Deficiency Promotes APP Processing in a SARM1-Dependent Manner.Cells · 2026Article
- Targeting the SARM1-cADPR-CaArthritis research & therapy · 2026Article
- NADThe EMBO journal · 2026Article
- The rise and fall of SARM1 base-exchange inhibitors.Communications chemistry · 2026Article
- Quantification of SARM1 NADase Activity in Human Peripheral Blood Mononuclear Cells.FASEB journal : official publication of the Federation of American Societies for Experimental Biology · 2026Article
- Brain metabolomic profiling reveals ischemia-dominant disruption of metabolic pathways and tissue homeostasis in neonatal hypoxic-ischemic brain injury.Scientific reports · 2026Article
- Potent Neuronal Nicotinamide Adenine Dinucleotide-Boosting Tetrahydroquinoxalines: Structure-Activity Relationships and Early Drug Metabolism and Pharmacokinetics Evaluation.ACS medicinal chemistry letters · 2026Article
- The Mitochondrial Guardian α-Amyrin Mitigates Alzheimer's Disease Pathology via Modulation of the DLK-SARM1-ULK1 Axis.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
134 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
Authors and funding
25 authors at 5 institutions in 4 countries.
Matthew D FigleyDepartment of Developmental Biology, Washington University School of Medicine in Saint Louis, St. Louis, MO, USA; Needleman Center for Neurometabolism and Axonal Therapeutics, Washington University School of Medicine in Saint Louis, St. Louis, MO, USA.
Weixi GuSchool of Chemistry and Molecular Biosciences, Institute for Molecular Bioscience and Australian Infectious Diseases Research Centre, University of Queensland, Brisbane, QLD 4072, Australia.
Jeffrey D NansonSchool of Chemistry and Molecular Biosciences, Institute for Molecular Bioscience and Australian Infectious Diseases Research Centre, University of Queensland, Brisbane, QLD 4072, Australia.
Yun ShiInstitute for Glycomics, Griffith University, Southport, QLD 4222, Australia.
Yo SasakiNeedleman Center for Neurometabolism and Axonal Therapeutics, Washington University School of Medicine in Saint Louis, St. Louis, MO, USA; Department of Genetics, Washington University School of Medicine in Saint Louis, St. Louis, MO, USA.
Katie CunneaEvotec (UK) Ltd., 114 Innovation Drive, Milton Park, Abingdon, Oxfordshire OX14 4RZ, UK; Evotec SE, Manfred Eigen Campus, Essener Bogen 7, 22419 Hamburg, Germany.
Alpeshkumar K MaldeInstitute for Glycomics, Griffith University, Southport, QLD 4222, Australia.
Xinying JiaCentre for Advanced Imaging, University of Queensland, Brisbane, QLD 4072, Australia.
Zhenyao LuoSchool of Chemistry and Molecular Biosciences, Institute for Molecular Bioscience and Australian Infectious Diseases Research Centre, University of Queensland, Brisbane, QLD 4072, Australia.
Forhad K SaikotSchool of Chemistry and Molecular Biosciences, Institute for Molecular Bioscience and Australian Infectious Diseases Research Centre, University of Queensland, Brisbane, QLD 4072, Australia.
Tamim MosaiabInstitute for Glycomics, Griffith University, Southport, QLD 4222, Australia.
Veronika MasicInstitute for Glycomics, Griffith University, Southport, QLD 4222, Australia.
Stephanie HoltInstitute for Glycomics, Griffith University, Southport, QLD 4222, Australia.
Lauren Hartley-TassellInstitute for Glycomics, Griffith University, Southport, QLD 4222, Australia.
Helen Y McGuinnessSchool of Chemistry and Molecular Biosciences, Institute for Molecular Bioscience and Australian Infectious Diseases Research Centre, University of Queensland, Brisbane, QLD 4072, Australia.
Mohammad K ManikSchool of Chemistry and Molecular Biosciences, Institute for Molecular Bioscience and Australian Infectious Diseases Research Centre, University of Queensland, Brisbane, QLD 4072, Australia.
Todd BosanacDisarm Therapeutics, a wholly owned subsidiary of Eli Lilly & Co., Cambridge, MA, USA.
Michael J LandsbergSchool of Chemistry and Molecular Biosciences, Institute for Molecular Bioscience and Australian Infectious Diseases Research Centre, University of Queensland, Brisbane, QLD 4072, Australia.
Philip S KerryEvotec (UK) Ltd., 114 Innovation Drive, Milton Park, Abingdon, Oxfordshire OX14 4RZ, UK; Evotec SE, Manfred Eigen Campus, Essener Bogen 7, 22419 Hamburg, Germany.
Mehdi MobliCentre for Advanced Imaging, University of Queensland, Brisbane, QLD 4072, Australia.
Robert O HughesDisarm Therapeutics, a wholly owned subsidiary of Eli Lilly & Co., Cambridge, MA, USA.
Jeffrey MilbrandtNeedleman Center for Neurometabolism and Axonal Therapeutics, Washington University School of Medicine in Saint Louis, St. Louis, MO, USA; Department of Genetics, Washington University School of Medicine in Saint Louis, St. Louis, MO, USA. Electronic address: jmilbrandt@wustl.edu.
Bostjan KobeSchool of Chemistry and Molecular Biosciences, Institute for Molecular Bioscience and Australian Infectious Diseases Research Centre, University of Queensland, Brisbane, QLD 4072, Australia. Electronic address: b.kobe@uq.edu.au.
Aaron DiAntonioDepartment of Developmental Biology, Washington University School of Medicine in Saint Louis, St. Louis, MO, USA; Needleman Center for Neurometabolism and Axonal Therapeutics, Washington University School of Medicine in Saint Louis, St. Louis, MO, USA. Electronic address: diantonio@wustl.edu.
Thomas VeInstitute for Glycomics, Griffith University, Southport, QLD 4222, Australia. Electronic address: t.ve@griffith.edu.au.
The University of Queensland · AUGriffith University · AUWashington University in St. Louis · USEli Lilly (United States) · USEvotec (Germany) · DE
Funding
Washington University Nutrition Obesity Research CenterP30DK056341 · NIDDK · WASHINGTON UNIVERSITY · PI Dominic N Reeds · 1999 to 2026
$30.2MPHYSIOLOGY AND GENETICS OF THE GDNF HOMOLOG NEURTURINR01AG013730 · NIA · WASHINGTON UNIVERSITY · PI JEFFREY D MILBRANDT · 1996 to 2026
$10.6MDISSECTION OF SARM1-INDUCED AXON DEGENERATION AND CELL DEATHR01NS087632 · NINDS · WASHINGTON UNIVERSITY · PI Aaron Diantonio, JEFFREY D MILBRANDT · 2014 to 2026
$6.4MRegulating NAD Metabolism to Inhibit Axon Degeneration in Neurodegenerative DiseasesRF1AG013730 · NIA · WASHINGTON UNIVERSITY · PI MILBRANDT, JEFFREY D · 2017 to 2017
$2.8M(PQ#9) Promoting Axon Stability to Prevent Therapy-induced Peripheral NeuropathyR01CA219866 · NCI · WASHINGTON UNIVERSITY · PI DIANTONIO, AARON, MILBRANDT, JEFFREY D · 2017 to 2021
$2.3MNCI NIH HHS R01 CA219866NIA NIH HHS R01 AG013730NIA NIH HHS RF1 AG013730NIDDK NIH HHS P30 DK056341NINDS NIH HHS R01 NS087632
Abstract
Axon degeneration is a central pathological feature of many neurodegenerative diseases. Sterile alpha and Toll/interleukin-1 receptor motif-containing 1 (SARM1) is a nicotinamide adenine dinucleotide (NAD
Indexed as
AnimalsArmadillo Domain ProteinsAxonsCytoskeletal ProteinsEnzyme ActivationHEK293 CellsHumansMiceMice, KnockoutModels, MolecularMolecular Dynamics SimulationMutagenesisNADNerve DegenerationNicotinamide MononucleotideNicotinamide-Nucleotide AdenylyltransferaseArmadillo Domain ProteinsCytoskeletal ProteinsNADNicotinamide MononucleotideNicotinamide-Nucleotide AdenylyltransferaseNmnat2 protein, mouseSARM1 protein, mouseallosteryARM domaincryo-EMNADasenicotinamide ribosideTIR domainX-ray crystallography
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.